Anne Tsatsaris

TL;DR: Prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion.

TL;DR: In conclusion, platelet inhibition in ATLANTIC was unaffected by pre-hospital ticagrelor administration at the time of initial angiogram due to the short transfer delay, and Morphine administration was associated with delayed onset of action of ticgrelor and appeared more important than timing of tICag Relor administration.

TL;DR: The ATLANTIC study as discussed by the authors is a 30-day international, randomized, parallel-group, placebo-controlled study in male and female patients (aged ≥18 years) who are diagnosed as having acute ST-segment elevation myocardial infarction (STEMI), with intended primary percutaneous coronary intervention (PCI).

TL;DR: The ATLANTIC-H 24 study as mentioned in this paper evaluated the effects of pre-hospital ticagrelor during the first 24 hours after primary percutaneous coronary intervention (PCI) in the ATLANTICA (administration of ticagrarelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the Coronary artery) study.

TL;DR: Morphine-treatment was associated with increased GP IIb/IIIa inhibitor use, less pre-PCI TIMI 3 flow, and more bleeding, and judicious morphine use is advised with non-opioid analgesics preferred for non-severe acute pain.